Introduction: Coordinated Global Action Is Needed to Combat Antimicrobial Resistance

  • I. W. FongEmail author
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)


Antimicrobial resistance is a global dilemma that threatens the health and safety of populations in all countries of the world. Urgent actions are needed to be taken before it reaches a critical stage, when large numbers of people in communities cannot be treated for life-threatening infections due to lack of effective drugs. Although the threat is most imminent from antibacterial resistance to commonly used antibiotics for infections seen regularly in intensive care units and hospitals, it is more prevalent and widespread and involves a wide spectrum of microbes. This second edition of “Antimicrobial Resistance and Implications for the 21st Century” provides not only updates and advances since the original edition but provides a wider spectrum of topics in the issue. Although most chapters of this new edition address issues of common bacterial resistance, others provide up-to-date reviews on resistancetrends with viruses, including human immunodeficiency virus [HIV] and human herpes group of viruses.


  1. 1.
    Historical introduction. In: Greenwood D, Davey P, Wilcox M, editors. Antimicrobial chemotherapy. 5th ed. Oxford, UK: Oxford University Press; 2007. p. 1–10.Google Scholar
  2. 2.
    Davies J, Davies D. Origins of antibioptic resistance. Microbiol Mol Biol Rev. 2010;74:417–33.CrossRefGoogle Scholar
  3. 3.
    Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl. 1):S5–12.CrossRefGoogle Scholar
  4. 4.
    Landman D, Gergescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449–65.CrossRefGoogle Scholar
  5. 5.
    Gillings MR. Integrons: past, present and future. Microbiol Mol Biol Rev. 2014;778:257–77.CrossRefGoogle Scholar
  6. 6.
    Nathon C. Fresh approaches to anti-infective therapies. Sci Transl Med. 2012;4:140r2.Google Scholar
  7. 7.
    Hughes VM, Datta N. Conjugative plasmids in bacteria of the ‘pre-antibiotic’ era. Nature. 1983;302:725–6.CrossRefGoogle Scholar
  8. 8.
    D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011;477:457–61.CrossRefGoogle Scholar
  9. 9.
    Deak D, Outterson K, Powers JH, Kesselhelm AS. Progress in the fight against multi-resistant bacteria? A review of US Food and Drug Administration—approved antibiotics, 2010–2015. Ann Intern Med. 2016;165:363–72.CrossRefGoogle Scholar
  10. 10.
    Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112:5649–54.CrossRefGoogle Scholar
  11. 11.
    Speksnijder DC, Mevius D, Bruscheke CJ, Wagenaar JA. Reduction of veterinary antimicrobial use in the Netherlands. The Dutch success model. Zoonoses Public Health. 2015;62(Suppl 1):79–87.CrossRefGoogle Scholar
  12. 12.
    Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travelers [COMBAT study]: a prospective, multicenter cohort study. Lancet Infect Dis. 2017;17:78–85.CrossRefGoogle Scholar
  13. 13.
    Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K, Davies S. Antimicrobials: access and sustainable effectiveness 1. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168–75.CrossRefGoogle Scholar
  14. 14.
    Hamprecht A, Rohde AM, Behnke M, et al. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Chemother. 2016;71:2957–63.Google Scholar
  15. 15.
    Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction—based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61:1071–80.CrossRefGoogle Scholar
  16. 16.
    Wagner B, Filice GA, Drekonja D, et al. Antimicrobial stewardship programs in inpatient hospital settings: a systematic review. Infect Control Hosp Epidemiol. 2014;35:1209–28.CrossRefGoogle Scholar
  17. 17.
    Centers for Disease control and Prevention [CDC]. Office-related antibiotic prescribing for persons aged ≤ 14 years—United States, 1993–1994 to 2007–2008. MMWR Morb Mortal Wkly Rep. 2011;60:1153–6.Google Scholar
  18. 18.
    Lee GC, Reveles KR, Attridge RT, et al. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014;12:96.CrossRefGoogle Scholar
  19. 19.
    Jones BE, Sauer B, jones MM, et al. Variation in outpatient antibiotic prescribing for acute respiratory infections in the veteran population. A cross-sectional study. Ann Intern Med. 2015;163:73–80.CrossRefGoogle Scholar
  20. 20.
    Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA. 2016;315:1864–73.CrossRefGoogle Scholar
  21. 21.
    Little P, Moore M, Kelly J, et al. the PIPS Investigators. Delayed antibiotic prescribing strategies for respiratory tract infections in primary care: pragmatic, factorial, randomized controlled trial. BMJ. 2014;348:g1606.CrossRefGoogle Scholar
  22. 22.
    Dar OA, Hasa R, Schlundt J, et al. Antimicrobials: access and sustainable effectiveness. Exploring the evidence base for national and regional policy interventions to combat resistance. Lancet. 2016;387:285–95.CrossRefGoogle Scholar
  23. 23.
    Spellberg B, Blaser M, Guidos RJ, et al. Infectious Disease Society of America [IDSA]. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397-428.Google Scholar
  24. 24.
    Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. 2016. Accessed at
  25. 25.
    WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Accessed at On 31 Mar 2017.
  26. 26.
    Slayton RB, Toth D, Lee BY, et al. Estimated effects of a coordinated approach for action to reduce antibiotic-resistant infections in health care facilities—United States. MMWR Morb Mortal Wkly Rep. 2015;64:826.CrossRefGoogle Scholar
  27. 27.
    Cheng AC, Turnbridge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis. 2012;18:1453–60.CrossRefGoogle Scholar
  28. 28.
    Zhu YG, Zhao Y, Li B, et al. Continental-scale pollution of estuaries with antibiotic resistant genes. Nat Microbiol. 2017;2:16270.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations